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The pattern‑recognition molecule 
H‑ficolin in relation to diabetic 
kidney disease, mortality, 
and cardiovascular events in type 1 
diabetes
Jakob Appel Østergaard1,2,11, Fanny Jansson Sigfrids3,4,5,11, Carol Forsblom3,4,5, 
Emma H. Dahlström3,4,5, Lena M. Thorn3,4,5,6, Valma Harjutsalo3,4,5,7, Allan Flyvbjerg8, 
Steffen Thiel9, Troels Krarup Hansen2 & Per‑Henrik Groop 3,4,5,10*
H‑ficolin recognizes patterns on microorganisms and stressed cells and can activate the lectin 
pathway of the complement system. We aimed to assess H‑ficolin in relation to the progression of 
diabetic kidney disease (DKD), all‑cause mortality, diabetes‑related mortality, and cardiovascular 
events. Event rates per 10‑unit H‑ficolin‑increase were compared in an observational follow‑up of 
2,410 individuals with type 1 diabetes from the FinnDiane Study. DKD progression occurred in 400 
individuals. The unadjusted hazard ratio (HR) for progression was 1.29 (1.18–1.40) and 1.16 (1.05–
1.29) after adjustment for diabetes duration, sex,  HbA1c, systolic blood pressure, and smoking status. 
After adding triglycerides to the model, the HR decreased to 1.07 (0.97–1.18). In all, 486 individuals 
died, including 268 deaths of cardiovascular causes and 192 deaths of complications to diabetes. 
HRs for all‑cause mortality and cardiovascular mortality were 1.13 (1.04–1.22) and 1.05 (0.93–1.17), 
respectively, in unadjusted analyses. These estimates lost statistical significance in adjusted models. 
However, the unadjusted HR for diabetes‑related mortality was 1.19 (1.05–1.35) and 1.18 (1.02–1.37) 
with the most stringent adjustment level. Our results, therefore, indicate that H‑ficolin predicts 
diabetes‑related mortality, but neither all‑cause mortality nor fatal/non‑fatal cardiovascular events. 
Furthermore, H‑ficolin is associated with DKD progression, however, not independently of the fully 
adjusted model.
Type 1 diabetes is a prevalent, chronic disease associated with several metabolic disturbances. Despite an opti-
mized standard of care, the disease remains accompanied by excess morbidity and mortality, mostly mediated 
by its long-term micro- and macrovascular  complications1,2.
The pattern-recognition molecules of the complement system, such as H-ficolin (also known as Ficolin-3) 
and mannan-binding lectin (MBL), bind specific molecular patterns that may be present on the surface of 
microorganisms and can thereby activate the lectin pathway of the complement system. As a consequence, an 
inflammatory reaction may  evolve3. In the Steno Diabetes cohort in Denmark, we have previously shown that 
H-ficolin is associated with an increased risk of incident microalbuminuria in type 1  diabetes4, and MBL has 
been linked to diabetic kidney disease (DKD) in both type  15–7 and type 2  diabetes8. A recent study compared 
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all-cause mortality in individuals with type 1 diabetes grouped by genetically determined differences in MBL 
concentration and found a higher mortality rate among individuals with genotypes encoding high MBL con-
centrations – possibly suggesting a causal  relationship9.
Hyperglycemia alters glycans enzymatically through the hexosamine pathway as well as non-enzymatically by 
the formation of advanced glycation end-products10,11. These glycan alterations are proposed to cause an adverse 
complement auto-attack initiated by pattern-recognition molecules. In line with this, MBL promotes diabetic 
kidney changes and accumulates in multiple tissues in experimental models of  diabetes12–16.
Taken together, clinical and preclinical studies point towards an auto-attack from the complement system in 
diabetes, and the pattern-recognition molecules have emerged as potential culprits in the pathogenesis of late 
diabetic complications. In this study, we aimed to validate the previously observed association of H-ficolin con-
centration and incident microalbuminuria in a nationwide, multicenter Finnish cohort of individuals with type 
1 diabetes. Additionally, we aimed to examine whether H-ficolin concentration is associated with the progression 
of DKD as well as with mortality and cardiovascular outcomes in a large and well-characterized population of 
individuals with type 1 diabetes.
Results
Baseline characteristics. This study included 2,410 individuals with type 1 diabetes from the Finnish Dia-
betic Nephropathy (FinnDiane) Study. The baseline clinical characteristics of the study participants, stratified 
by median H-ficolin concentration (31.18 μg/ml) at baseline, are summarized in Table 1. In brief, those in the 
group of higher H-ficolin concentration had also higher systolic and diastolic blood pressure, higher  HbA1c, and 
were more often current or former smokers. There was also a clear difference in the sex distribution between the 
groups, as a larger proportion of those with higher H-ficolin were men. However, we did not observe any differ-
ence in mean age or diabetes duration. Individuals with high H-ficolin were more likely to have more advanced 
stages of DKD, whereas the difference in eGFR was not significant after correction for multiple testing.
Furthermore, individuals in the category of higher H-ficolin had a poorer lipid profile compared to those 
in the other group, as also shown in Table 1. The associations between lipids and H-ficolin concentration were 
Table 1.  Baseline characteristics by median H-Ficolin concentration. Data are presented as mean (standard 
deviation), median [interquartile range], or n (%). P19 tests, p-value after Bonferroni correction for the total 
number of tests; BMI, body mass index; RAAS, renin–angiotensin–aldosterone system;  HbA1c, glycated 
hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein, DKD, diabetic kidney disease; 




 ≥ 31.18 μg/ml P P19 tests
n 1205 1205
Sex (woman) 711 (59.0%) 432 (35.9%)  < 0.001  < 0.001
Age (years) 36.7 (11.3) 37.5 (11.4) 0.11 1
Diabetes duration (years) 21.4 (12.1) 21.7 (11.3) 0.51 1
Diabetes onset age (years) 15.3 (8.8) 15.8 (9.1) 0.23 1
BMI (kg/m2) 24.7 (3.4) 25.3 (3.7)  < 0.001  < 0.001
Systolic blood pressure (mmHg) 133 (19) 136 (19)  < 0.001 0.004
Diastolic blood pressure (mmHg) 79 (10) 81 (11)  < 0.001  < 0.001
Retinal laser treatment (yes) 436 (36.4%) 503 (42.1%) 0.005 0.95
RAAS inhibitor (yes) 316 (26.4%) 440 (36.9%)  < 0.001  < 0.001
Lipid-lowering medication (yes) 91 (7.6%) 149 (12.5%)  < 0.001 0.002
Smoking status  < 0.001  < 0.001
Current 225 (19.5%) 322 (28.4%)
Former 257 (22.3%) 266 (23.4%)
Never 673 (58.3%) 547 (48.2%)
HbA1c (mmol/mol) 66.9 (15.9) 71.2 (16.1)  < 0.001  < 0.001
Total cholesterol (mmol/l) 4.86 (0.91) 5.19 (1.08)  < 0.001  < 0.001
HDL-cholesterol (mmol/l) 1.29 (0.35) 1.18 (0.35)  < 0.001  < 0.001
Triglycerides (mmol/l) 0.99 [0.77, 1.42] 1.23 [0.87, 1.81]  < 0.001  < 0.001
LDL-cholesterol (mmol/l) 3.03 (0.83) 3.33 (0.93)  < 0.001  < 0.001
DKD category at baseline  < 0.001  < 0.001
Normal AER 750 (62.2%) 662 (54.9%)
Microalbuminuria 152 (12.6%) 161 (13.4%)
Macroalbuminuria 182 (15.1%) 272 (22.6%)
ESRD 121 (10.0%) 110 (9.1%)
eGFR (ml/min/1.73  m2) 84 [67, 100] 83 [61, 99] 0.04 0.76
AER (mg/24 h) 11 [6, 41] 16 [7, 121]  < 0.001  < 0.001
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confirmed in additional correlation analyses, which revealed that the correlation with triglycerides was the 
strongest (r = 0.26, p < 0.001, data not shown).
H‑ficolin in relation to diabetic kidney disease. The mean H-ficolin concentration was higher with 
increasing stage of albumin excretion rate (AER) at baseline: 31.1 (10.0) µg/ml, 32.3 (10.6) µg/ml, and 33.9 
(10.6) µg/ml in individuals with normal AER, microalbuminuria, and macroalbuminuria, respectively (p for 
trend < 0.001). Notably, individuals on dialysis had higher H-ficolin concentrations (41.2 [13.9] µg/ml, n = 69) 
than those with prior kidney transplantation (27.4 [9.2] µg/ml, n = 162), p < 0.001.
Of the 2,098 individuals with confirmed DKD status, 400 (19.1%) progressed during follow-up (141 [35.2%] 
to microalbuminuria, 60 [15.0%] to macroalbuminuria, 199 [49.8%] to end-stage renal disease, ESRD). The 
median [interquartile; IQR] follow-up time for the DKD outcomes was 7.9 [5.2, 13.4] years. With all events of 
progression pooled, the mean H-ficolin concentration was higher in those who progressed (34.5 [10.8] µg/ml) 
than those who did not (31.2 [10.0] µg/ml), p < 0.001. Likewise, among the individuals with initial normal AER 
and microalbuminuria, the mean H-ficolin concentration (µg/ml) was higher among progressors (34.2 [10.8] 
and 35.0 [10.3]) than non-progressors (30.1 [9.9] and 31.6 [10.3]), p < 0.001 and p = 0.02, respectively. A similar 
pattern, although non-significant, was seen in the individuals who progressed from macroalbuminuria to ESRD: 
34.5 (11.0) vs. 33.5 (10.3) µg/ml, p = 0.29.
The Kaplan–Meier plots in Fig. 1a illustrate the cumulative progression of DKD stratified by quartiles of 
H-ficolin concentration. The highest cumulative DKD progression was observed among those in the highest 
quartile of H-ficolin—while, as shown in the figure, the progression rate among the two lowest quartiles did 
not diverge.
Results from the Cox proportional hazard analyses exploring the relationship between H-ficolin and progres-
sion of DKD are presented in Table 2. The unadjusted hazard ratios (HRs) for a 10-unit increase of H-ficolin (all 
events of DKD progression pooled) was 1.29 (1.18–1.40), p < 0.001, and 1.16 (1.05–1.29), p = 0.003, after adjust-
ment with diabetes duration, sex,  HbA1c, systolic blood pressure, and history of smoking. However, in the final 
model further including triglycerides, the HR decreased to 1.07 (0.97–1.18), p = 0.19.
The HR for incident microalbuminuria was borderline significant after adjustment with diabetes duration, 
sex,  HbA1c, systolic blood pressure, and history of smoking (1.18 [1.00–1.39]), p = 0.05, however, neither this 
association was independent of triglycerides (HR 1.13 [0.93–1.34], p = 0.15). Regarding progression to macroal-
buminuria and ESRD, none of the multivariable analyses remained significant for H-ficolin, as shown in Table 2.
H‑ficolin in relation to mortality. A total of 486 participants died during follow-up. Regarding mortal-
ity, the individuals were followed for 16.5 (14.9–17.2) years. The mean concentration of H-ficolin was higher in 
those who died (33.0 [11.8] μg/ml) compared to those who did not (31.5 [10.1] μg/ml), p = 0.008. Altogether 
268 deaths (55.1%) were due to cardiovascular causes and 192 (39.5%) to complications of diabetes. Of these, 
63 deaths belonged to both groups. The mean H-ficolin concentration was no different (p = 0.52) stratified by 
cardiovascular mortality status, whereas individuals who died of diabetes-related causes had a higher mean 
H-ficolin (33.7 [12.1] μg/ml) than those who did not (31.7 [10.3] μg/ml), p = 0.008.
The highest quartile of H-ficolin also expressed the highest cumulative all-cause mortality as well as mortal-
ity from diabetes-related causes, as illustrated in Fig. 1b,c. Yet, there was no difference between the three lower 
quartiles regarding either of the outcomes (log-rank p-value 0.89 and 0.89).
Table 3 shows the different steps of Cox proportional hazards analyses for all-cause, cardiovascular, and 
diabetes-related mortality. Summarized, with the most stringent level of adjustment including diabetes duration, 
sex,  HbA1c, systolic blood pressure, history of smoking, triglycerides, and DKD category of baseline (Model 5), 
only the association between H-ficolin and diabetes-related mortality remained significant (HR 1.18 [1.02–1.37], 
p = 0.02). As the cumulative incidences for all-cause and diabetes-related mortality were the highest for quartile 
4 (Q4), we also performed the Cox regression analyses comparing Q4 with Q1-3 combined. Adjusting for Model 
5, the HR for Q4 regarding all-cause mortality was 1.26 (1.02–1.56), p = 0.03, and 1.62 (1.15–2.27), p = 0.005, 
regarding mortality attributable to complications of diabetes.
H‑ficolin in relation to cardiovascular events. For CHD and stroke, the median [IQR] follow-up time 
was 16.7 [15.2, 17.3] and 16.9 [15.6, 17.3] years, respectively. The individuals who experienced an incident CHD 
event were characterized by a higher mean H-ficolin concentration (33.4 [10.3]) than their counterparts who 
did not (31.6 [10.5]), p = 0.003. However, we did not observe a difference in H-ficolin concentration stratified by 
incident stroke (32.7 [10.5] vs. 31.6 [10.5]), p = 0.24.
The cumulative incidence of CHD increased stepwise with increasing quartile of H-ficolin concentration, as 
Fig. 1d shows (log-rank p = 0.02). The HR for a 10-unit increase in H-ficolin concentration was 1.15 (1.05–1.26), 
p = 0.003 in unadjusted analysis, and 1.13 (1.03–1.25), p = 0.01, after adjustment for diabetes duration and sex. 
However, this association was not significant after further adjustments (Table 3). As presumed from the uni-
variate analysis, the Cox regressions yielded no significant associations between H-ficolin and stroke (Table 3).
Discussion
Findings from experimental and clinical studies are pointing towards inflammation and the complement system 
contributing to the pathogenesis of diabetic complications, particularly DKD. H-ficolin is a pattern-recognition 
molecule that can activate the lectin pathway of the complement system by recognition of specific carbohydrate 
or acetyl-patterns on the surface of microorganisms or altered self-cells17,18. The lectin pathway targets comple-
ment activation based on the reaction between pattern-recognition molecules (including H-ficolin) and so-called 
pathogen-associated molecular patterns (PAMPs) on non-self surfaces, as well as damage- or danger-associated 
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Figure 1.  Kaplan–Meier curves, comparing individuals stratified by quartiles of H-ficolin concentration at 
baseline, with respect to (a) progression of diabetic kidney disease (DKD), (b) all-cause mortality, (c) diabetes-
related mortality, and (d) coronary heart disease (CHD). Quartile 1 (Q1), black solid line; quartile 2 (Q2), red 
dashed line; quartile 3 (Q3), grey dotted line; quartile 4 (Q4), orange dot-dashed line.
Table 2.  Cox proportional hazards analysis with different levels of adjustment for DKD progression. Hazard 
ratios (HRs) are presented for a 10-unit increase in H-ficolin concentration. Model 1: Unadjusted. Model 2: 
Diabetes duration and sex. Model 3: Model 2 +  HbA1c, systolic blood pressure, and smoking status. Model 4: 
Model 3 + triglycerides.
Number of 
individuals Number of events Model 1 Model 2 Model 3 Model 4
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molecular patterns (DAMPs) on self-cells, such as apoptotic cells. In the Steno Diabetes cohort, we previously 
found that circulating H-ficolin concentration is associated with incident microalbuminuria in individuals with 
newly diagnosed type 1 diabetes, independent of  HbA1c, systolic blood pressure, smoking, and baseline urinary 
 AER4. In the present study, we aimed to investigate this relationship in further detail in a larger cohort with more 
events, including progression to the more advanced stages of DKD. In a cross-sectional setting, we observed 
increasing H-ficolin concentrations with a more advancing level of DKD at baseline. Even though H-ficolin was 
associated with the pooled outcome of DKD progression as well as incident microalbuminuria separately, these 
associations lost statistical significance in the final model that adjusted for triglycerides in addition to diabetes 
duration, sex,  HbA1c, systolic blood pressure, and smoking (i.e., traditional risk factors for DKD progression and 
the other outcomes of the study). H-ficolin was not associated with the incidence of macroalbuminuria or ESRD. 
Although the low number of progressors from micro- to macroalbuminuria and ESRD may be a contributing 
factor, our observational study setting does not explain this discrepancy.
MBL is the classic activator of the lectin pathway of the complement system and has been linked to DKD 
as well as all-cause mortality in both type 1 and type 2  diabetes5–9,19. One of the main aims of our study was to 
add to this knowledge by assessing the association between the lectin pathway activator H-ficolin and mortal-
ity in type 1 diabetes. We found that individuals in the highest quartile of H-ficolin had the highest all-cause 
mortality during follow-up, as compared to the individuals with lower H-ficolin levels. However, even though 
an association between H-ficolin concentration and all-cause mortality was seen in the present study, it was 
not statistically significant in the adjusted analyses. On one hand, these results may reflect stronger predictive 
values of the covariates including  HbA1c, blood pressure, smoking, triglycerides, and AER as compared with 
H-ficolin. On the other hand, the covariates may be confounders but also a step on a causal pathway between 
H-ficolin and mortality. Mutations in the H-ficolin encoding FCN3 gene are rare and, therefore, it remains to 
be determined whether H-ficolin concentration per se may cause alterations in the covariates of our statistical 
 models20,21. This is of special interest as a correlation has been observed between the triglycerides and H-ficolin, 
both in this study and by  others22,23.
Cardiovascular, along with endocrine, causes have been the most frequently reported contributors to death 
in several cohorts of individuals with type 1  diabetes24–27. In line, the majority (55%) of deaths in this popula-
tion were due to cardiovascular disease (CVD). We did not observe any difference in the H-ficolin concentra-
tion between individuals who died from CVD causes as compared with those who did not, and moreover, the 
H-ficolin level did not predict CHD events or stroke in the adjusted models. Previous data on H-ficolin in CVD 
are sparse. H-ficolin level did not differ in a cross-sectional study of healthy subjects and patients with myocardial 
 infarction28. In ischemic stroke, a cross-sectional study found H-ficolin level to be inversely correlated to disease 
severity, which was speculated to be a consequence of H-ficolin binding to dying  cells29. More data exists for 
MBL in relation to CVD, in which MBL seems to act as a double-edged sword. In stroke and myocardial infarc-
tion, MBL is found to augment tissue damage most likely through reaction with altered self-surfaces whereas 
beneficial effects of MBL in tissue homeostasis are observed in the development of atherosclerotic  lesions30. Yet, 
although diabetic micro- and macrovascular complications tend to coincide, the present findings do not identify 
H-ficolin as the link.
One of the most intriguing findings from the present study was related to mortality due to complications of 
diabetes, an outcome confirmed from both register-based data and death certificates by FinnDiane researchers. 
In contrast to cardiovascular mortality, we found a robust association with all analyses, and the HR for diabetes-
related death for every 10-unit increase in H-ficolin concentration was 1.18-fold despite the most stringent level 
of adjustment, including baseline DKD stage. Previous studies from both the FinnDiane as well as other cohorts 
have established that the presence and the severity of renal complications is the main predictor of survival in type 
1  diabetes31–33. Notably, acute complications such as hypoglycemia or diabetic ketoacidosis constituted only a 
Table 3.  Cox proportional hazards analysis with different levels of adjustment for cardiovascular outcomes 
and mortality. Hazard ratios (HRs) are presented for a 10-unit increase in H-ficolin concentration. Model 
1: Unadjusted. Model 2: Diabetes duration and sex. Model 3: Model 2 +  HbA1c, systolic blood pressure, and 
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minority of the cases in our diabetes-related outcome, whereas insulin-dependent diabetes mellitus with multiple 
complications was the most frequently reported underlying cause of death.
The possible mechanistic pathway underlying the observed association has not been unraveled yet—however, 
we speculate that one explanation could be tissue remodeling and damage caused by diabetes. The terminal 
membrane-bound product of the complement cascade is the membrane-attack complex (MAC), which is a 
transmembrane pore that causes lysis of invading pathogens by osmotic stress. Healthy mammalian cells are 
normally protected from complement auto-attack by complement regulatory proteins that inhibit the comple-
ment cascade, for instance, CD59. However, hyperglycemia-induced glycation of CD59 in diabetes impairs the 
protection from complement auto-attack34,35. MAC-targeted endothelium cells have been found to stimulate 
mitosis of glomerular mesangial cells, which further supports the  view36.
The results of the present study need to be interpreted with attention to design strengths and weaknesses. 
The observational design prevents inference of causality. Also, the cumulative numbers of specific events may 
be too low to avoid statistical type 2 errors even in this large cohort of individuals with long observation time. 
However, the cohort is very well characterized and includes patients from multiple centers throughout Finland. 
Likewise, complete register-based coverage of cardiovascular events and mortality in addition to AER from the 
review of medical records are strengths of the study.
In conclusion, this study shows that high concentrations of serum H-ficolin predict mortality attributable to 
diabetes in adjusted analyses, whereas an association between H-ficolin and all-cause mortality was not observed 
in our cohort. No link between H-ficolin and cardiovascular events was detected, and despite that the association 
with DKD progression was independent of several well-established risk factors, it did not persist after adjustment 
with triglycerides. These results add to the existing knowledge of the complement system in long-term complica-
tions of type 1 diabetes. Yet, our findings stem from an observational study setting, and therefore, more research 
is needed to investigate possible causalities between H-ficolin and diabetes-related mortality.
Methods
Study population. The FinnDiane Study is a prospective, observational cohort study recruiting adult indi-
viduals with type 1 diabetes from multiple centers throughout Finland with the aim to detect risk factors for 
late diabetic complications in type 1 diabetes. The study was initiated in 1997 and the follow-up protocol has 
previously been described in  detail37. Only individuals with established type 1 diabetes have been recruited to 
the FinnDiane Study (International Classification of Diseases [tenth revision; ICD-10] classification code E10 
as a prerequisite), but as proof of a correct diagnosis, the subjects included in the present study were under the 
age of 40 years at diabetes onset and their insulin treatment was initiated within the first year from the diabetes 
diagnosis.
The participants underwent a thorough clinical examination at baseline. Information on co-morbidities 
and medication were obtained through questionnaires accompanied by drawing of blood samples and timed 
overnight or 24-h urine collections.  HbA1c was measured using standardized assays at the local diabetes centers. 
Smoking status was defined as current if the study participant had smoked at least one cigarette per day for at least 
one year. Participants who had stopped smoking before entering the FinnDiane study were considered former 
smokers. Kidney function was estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI)  formula38. Patients with undetermined DKD status at baseline (n = 68) were excluded from the analyses.
All study participants gave their written informed consent before inclusion. The study was conducted follow-
ing the Declaration of Helsinki and approved by the Ethics Committee of the Helsinki and Uusimaa Hospital 
District.
Outcomes. Follow-up data on kidney outcomes are recorded continuously for participants in the FinnDi-
ane study. AER was categorized as normal range (AER < 20 µg/min or < 30 mg/24 h or albumin-creatinine ratio 
[ACR] < 2.5 mg/mmol for men or < 3.5 mg/mmol for women), microalbuminuria (AER ≥ 20 and < 200 µg/min 
or ≥ 30 and < 300 mg/24 h or ACR ≥ 2.5 and < 25 mg/mmol for men or ≥ 3.5 and < 35 mg/mmol for women), or 
macroalbuminuria (AER ≥ 200 µg/min or ≥ 300 mg/24 h or ACR > 25 mg/mmol for men or > 35 mg/mmol for 
women). ESRD was defined as an ongoing need for dialysis or kidney transplantation. The most advanced DKD 
stage in two out of three consecutive urine collections preceding baseline was taken as the basis for the clas-
sification. Progression of DKD was defined as a change to a more advanced stage of AER or initiation of renal-
replacement therapy, confirmed from the medical files.
The analyses of cardiovascular events and mortality included events tracked through December 31, 2015. 
Non-fatal CVD events were retrieved from the Finnish National Care Register for Health Care, whereas the 
events of death were retrieved from the Finnish Cause of Death Register maintained by Statistics Finland. Only 
incident cases of CHD and stroke were included, hence, the study participants with events before the study 
baseline were excluded from these analyses. Death certificates were available for 98.8% of the deceased study 
participants. Cause of death was based on information reviewed from these by L.M.T., as well as on ICD-10 
codes provided by Statistics Finland. Mortality was defined as cardiovascular if the underlying and/or immedi-
ate cause of death was due to cardiovascular causes (ICD-10 I00-I99), and as diabetes-related if the cause was 
due to acute or chronic complications of the disease. The underlying cause of the diabetes-related death was 
chronic diabetes complications in 91.7% of the cases (n = 176) and acute complications in 8.3% (n = 16). Of the 
176 chronic complications, 75.0% were coded as E10.7 (Type 1 diabetes mellitus with multiple complications) and 
14.8% as E10.2 (Type 1 diabetes mellitus with kidney complications). The immediate causes of diabetes-related 
deaths were CVD (31.8%, n = 61), infections (28.1%, n = 54), chronic diabetes complications (22.9%, n = 44), and 
acute diabetes complications (10.9%, n = 21). The remaining causes were unclear (6.3%, n = 12) and, therefore, 
categorized only based on the underlying cause. Events of coronary heart disease (CHD) were defined as cases 
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of myocardial infarction (ICD-10 121-I22, ICD-8/9 410), coronary artery bypass grafting, and percutaneous 
coronary intervention (procedure codes TFN40, FN1AT, FN1BT, FN1YT, FNF, FNG, FNA, FNB, FNC, FND, 
FNE since 1996 and 5311–5315 between the years 1983 and 1995).
H‑ficolin. Quantification of the H-ficolin concentration was performed blinded to subject identity as previ-
ously described using normal human serum as standard except for a few  changes39. In brief, serum was thawed, 
diluted in assay buffer, and added to microtiter wells (FluoroNunc, Thermo Scientific, Waltham, MA, USA) 
coated with acetylated bovine serum albumin (B2518, Sigma-Aldrich, St. Louis, MO, USA), which is recog-
nized by H-ficolin. Standards, samples, and controls were added automatically to plates using a Janus Varispan 
automated work-station (PerkinElmer, Waltham, MA, USA). In-house biotinylated anti-H-ficolin antibody, 
europium-labelled streptavidin (PerkinElmer) and enhancement solution (Ampliqon, Odense, Denmark) were 
added in successive steps with triple washing in between. The europium fluorescence intensity was detected with 
a Victor X5 fluorometer (PerkinElmer). Intra-assay and inter-assay coefficients of variation were below 10% and 
16%, respectively. H-ficolin concentration was used as a predictor as a continuous variable as well as by compar-
ing subjects grouped according to H-ficolin quartiles.
Statistical analysis. Continuous variables were compared with Student’s t-test (two groups) or ANOVA 
(several groups) and expressed as mean (standard deviation; SD) if the data were normally distributed or with 
Mann–Whitney U-test and expressed as median [IQR] if the data distribution was skewed. Categorical vari-
ables were expressed as n (%) and compared between the groups using χ2 test. Multiple testing was addressed 
by Bonferroni correction. There was no interaction between H-ficolin and sex for any of the outcomes, hence, 
men and women were pooled in the analyses. Time-to-event was illustrated by Kaplan–Meier plots and the log-
rank test was used to compare survival distributions between quartiles of H-ficolin concentration. In addition, 
Cox proportional hazards analyses were used to estimate the HRs after adjustment for risk factors. The HRs 
are presented with 95% confidence interval for a 10-unit increase in H-ficolin concentration. The relationship 
between H-ficolin and components of the lipid profile were assessed with correlation analyses. Data analysis was 
performed with R open-source software version 3.5.1 (http://r- proje ct. org). Two-sided p-values below 5% were 
considered statistically significant.
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